0001193125-26-219375
SEC filingPepGen reported narrower losses and improved EPS in Q1 FY2026 versus Q1 FY2025, reflecting reduced operating expenses and disciplined capital allocation; however, the company remains fully dependent on external manufacturing partners and continues to fund operations through equity financing.
Operating income for Q1 FY2026 was ($18.9M), an improvement of 39.5% year-over-year from ($31.3M) in Q1 FY2025. Net income improved similarly — to ($17.8M) from ($30.2M) — and diluted EPS strengthened to ($0.26) from ($0.92). These improvements reflect lower operating expenses, as confirmed by management commentary citing strategic cost discipline and program prioritization. While the authoritative financial packet does not quantify specific expense drivers, the business context confirms that operating expense reductions are tied to the timing of manufacturing campaigns and personnel-related costs — consistent with PepGen’s asset-light, outsourced development model.
Since inception in January 2018, PepGen has funded operations primarily through equity offerings — including common and convertible preferred stock — and expects to continue doing so until substantial product revenue is achieved. There is no indication in the authoritative financial or business context packets of debt financing, collaborations, or licensing arrangements contributing to liquidity in Q1 FY2026. The absence of such activity underscores the company’s continued reliance on shareholder capital and highlights the importance of maintaining investor confidence during clinical advancement. With no near-term path to revenue, cash runway sustainability depends on the timing and size of future equity raises — a dynamic explicitly acknowledged in management’s forward-looking commentary on capital resources.